RCS - Oxford BioDynamics - CiRT: Real World Data Presented at ASCO-GI

Oxford BiodynamicsAnnouncement

23/01/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250123:nRSW3660Ua&default-theme=true

RNS Number : 3660U  Oxford BioDynamics PLC  23 January 2025

 

Oxford BioDynamics plc

("Oxford BioDynamics" or the "Company")

Oxford BioDynamics and Georgetown University Medical Center, Washington, DC

present real-world clinical utility data for the Checkpoint Inhibitor Response
Test

(EpiSwitch® CiRT) at ASCO-GI 2025

•    EpiSwitch CiRT is a first-of-its-kind precision medicine test of
high accuracy that predicts a patient's most likely response to Immune
Checkpoint Inhibitor (ICI) therapy

•    Georgetown University Medical Centre, Washington, DC will be
presenting CiRT evaluation data on a key cohort of patients with
Hepatocellular Carcinoma and Gastrointestinal Tumors

•    In patients treated with ICI therapy, the CiRT prediction of high
probability of response is associated with improved anti-cancer responses,
prolonged progression-free survival and significantly better outcomes

•    The American Society of Clinical Oncology Gastrointestinal Cancers
(ASCO-GI) annual meeting is attended by over 4,000 oncologists, oncology care
team members and pharma drug developers every year

 

Oxford, UK - 23 January 2025 - Oxford BioDynamics, Plc (AIM: OBD), a precision
clinical diagnostics company bringing specific and sensitive tests to the
practice of medicine based on its EpiSwitch® 3D genomics platform, announces
that Georgetown University Medical Center will be presenting significant data
related to the clinical utility of its flagship CiRT clinical assay at the
American Society of Clinical Oncology Gastrointestinal Cancers Symposium
(ASCO-GI), which is being held January 23 - 25, 2025, at the Moscone Center
West in San Francisco, CA.

 

Dr Aiwa Ruth He, MD, PhD of Georgetown University Medical Center, a
board-certified oncologist, and principal investigator of the collaborative
program with OBD, and Dr. Mahmoud Ouf, a clinical researcher at Lombardi
Cancer Center will present "Evaluation of EpiSwitch in Predicting
Immunotherapy Response in Hepatocellular Carcinoma and Gastrointestinal
Tumors" on Friday, January 24, 2025.

Liver cancer, particularly hepatocellular carcinoma, is a challenging and
deadly disease mainly due to frequent diagnoses at advanced stages when the
cancer has already spread or is inoperable, making treatment options limited.
Additionally, liver cancer is resistant to many standard therapies, and its
aggressive nature means that it can quickly become resistant to even newer
targeted treatments or immunotherapies. These factors combined make liver
cancer a particularly difficult disease to treat effectively. There is a need
for reliable molecular profiling tests, such as EpiSwitch CiRT, that can help
identify which class of drugs a patient is likely to respond to.

The presentation showcases that patients with a CiRT HP status (high
probability of response) were associated with improved anti-cancer responses,
prolonged progression-free survival (PFS), and better outcomes in
hepatocellular carcinoma (HCC) and other gastrointestinal (GI) tumors. The
mean Progression Free Survival (PFS) for the CiRT HP group was 30.7 months
compared to 13.3 months for the CiRT LP group (low probability of response).
These findings highlight CiRT's potential to address a critical unmet need for
reliable predictive biomarkers in liver and GI cancer treatment.

Dr. Alexandre Akoulitchev, Chief Scientific Officer of OBD said, "We are
excited that Georgetown will be sharing its CiRT evaluation data at the high
impact ASCO-GI annual meeting. It is a great opportunity to showcase the
real-world clinical utility behind our EpiSwitch CiRT assay in one of the
hardest diseases to treat in the world - liver cancer. We look forward to
showcasing the clinical advantages of CiRT and its strong predictions of GI
cancer patients who might have a robust response to immunotherapy or might
benefit instead from other treatment options. We are pleased with the outcomes
of this study."

Reference: Journal of Clinical Oncology, 43, 2025 (suppl 4; abstr 623)

-Ends-

For more information:

 Oxford BioDynamics PLC                                              +44 (0)1865 518910
 Matthew Wakefield, Non-Executive Chairman

 Paul Stockdale, CFO
 Shore Capital - Nominated Adviser and Joint Broker                  +44 (0)20 7408 4090
 Advisory: Stephane Auton / Lucy Bowden

 Broking: Fiona Conroy
 OAK Securities - Joint Broker                                       +44 (0)203 973 3678

 Jerry Keen / Henry Clarke / Damion Carruel
 WG Partners - Joint Broker                                          +44 (0)20 3705 9330

 David Wilson / Claes Spång / Satheesh Nadarajah / Erland Sternby
 Vigo Consulting  Media / Analyst enquiries for OBD                  +44 (0)20 7390 0230

Rozi Morris

                                                                     obd@vigoconsulting.com

 

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company,
advancing personalized healthcare by developing and commercializing precision
clinical diagnostic tests for life-changing diseases.

Currently OBD has two commercially available products: the EpiSwitch® PSE
(https://url.avanan.click/v2/___http:/www.94percent.com/___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjphZTRmOjE1ZmE3ZTA1NmFmMzlmYjIzZmFhOGU1NTc5MWI0OTdiODZmMjVmOTFlOWQ2YjBiZTM3YmNmMTMxMGYxOTcxMjI6cDpU)
 (EpiSwitch Prostate Screening test) and EpiSwitch® CiRT
(https://url.avanan.click/v2/___https:/www.mycirt.com/___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjpjZGI4OjQ3ZWJmMjU3YzNhNjYzYzNiYWVjZGNlMTJjZDM5ZGZkYzBlNmQyNTc0OTdlZWU4ZGI4ODFlYzU1OWZmN2JmMWE6cDpU)
 (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive
accuracy of a PSA test from 55% to 94% when testing the presence or absence of
prostate cancer. CiRT is a highly accurate (85%) predictive response test to
immuno-oncology checkpoint inhibitor treatments.

The tests are based on OBD's proprietary 3D genomic biomarker platform,
EpiSwitch® which enables screening, evaluation, validation and monitoring of
biomarkers to diagnose patients or determine how individuals might respond to
a disease or treatment.

OBD's clinical smart tests have the potential to be used across a broader
range of indications, and new tests are being developed in the areas of
oncology, neurology, inflammation, hepatology and animal health.

The Group's headquarters and UK laboratories are in Oxford, UK. Its US
operations and clinical laboratory are in Maryland, USA, along with a
reference laboratory in Penang, Malaysia.

OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more
information, please visit the Company's website, www.oxfordbiodynamics.com
(https://url.avanan.click/v2/___http:/www.oxfordbiodynamics.com___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6Njo3YmRiOmUxODM2ZWZhYmIxNjdhMjFiNTMxOThjNjE0YzMwYzg5YzA1MjI2MmYxMGY0ZTU1MzdjYzdlYzg1NDA5ZTcyOWU6cDpU)
,  X (@OxBioDynamics) or LinkedIn
(https://url.avanan.click/v2/___https:/www.linkedin.com/company/oxford-biodynamics___.YXAxZTpzaG9yZWNhcDphOm86ZGFiYjhlY2EwMWM5YWYzYjdhZjZhZmExZGM4OTMyMDg6NjozM2I4OmVmNzdkN2M0NmYxZDg3ODc0MWQ1NDEyMGQ4MjAxOWVmMTg4ZTMzNWY4MTA5NGE3NTE5ZDdlNWIwNjI5MTRhMTM6cDpU)
.

 

About ASCO-GI Symposium

The ASCO-GI Symposium is a crucial meeting for oncologists, focusing on the
latest advancements in the treatment and management of gastrointestinal
cancers, including colorectal, pancreatic, liver, esophageal, and gastric
cancers. The conference provides a platform for professionals to access
cutting-edge research, clinical trial data, and emerging therapies. It also
facilitates networking and collaboration among global experts, helping
oncologists stay current with new treatment protocols and innovative
technologies. ASCO-GI enables oncologists to enhance their clinical practice,
improve patient outcomes, and contribute to the advancement of the field
through knowledge exchange. ASCO-GI is known as the largest gathering of GI
oncologists in the world with the annual conference attracting more than 4,000
attendees and over 570 exhibitors.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAPKBBPKBKBADB